Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT01655693
Title Efficacy and Safety Doxorubicin Transdrug Study in Patients Suffering From Advanced Hepatocellular Carcinoma (ReLive)
Acronym ReLive
Recruitment Completed
Gender both
Phase Phase III
Variant Requirements No
Sponsors Onxeo
Indications
Therapies
Age Groups: adult
Covered Countries USA | TUR | LBN | ITA | HUN | FRA | ESP | DEU | BEL | AUT


No variant requirements are available.